No information is available on the clinical use of loncastuximab tesirine during breastfeeding. Because loncastuximab is a large protein molecule with a molecular weight of about 151,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] However, loncastuximab is conjugated with SG3249, a small-molecule alkylating agent that might enter milk and be absorbed by the infant. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that women not breastfeed during treatment and for 3 months after the final dose.
关于loncastuximab tesirine在母乳喂养期间的临床应用尚无可用信息。由于loncastuximab是一种分子量约为151,000 Da的大蛋白质分子，乳汁中的含量可能非常低。[1]它也可能在婴儿胃肠道中部分被破坏，婴儿的吸收可能极少。[2]然而，loncastuximab与小分子烷基化剂SG3249偶联，后者可能进入乳汁并被婴儿吸收。由于母乳喂养婴儿可能出现严重不良反应，制造商建议女性在治疗期间及最后一剂后3个月内不要进行母乳喂养。
Zotero 插件